CytomX Therapeutics Key Executives
This section highlights CytomX Therapeutics's key executives, including their titles and compensation details.
Find Contacts at CytomX Therapeutics
(Showing 0 of )
CytomX Therapeutics Earnings
This section highlights CytomX Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-06 | $-0.23 | $0.22 |
| Read Transcript | Q2 | 2024 | 2024-08-09 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-08 | $-0.08 | $0.17 |
| Read Transcript | Q4 | 2023 | 2024-03-11 | $0.00 | $0.01 |
| Read Transcript | Q3 | 2023 | 2023-11-08 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-08 | $-0.19 | $-0.02 |
| Read Transcript | Q1 | 2023 | 2023-05-09 | $-0.16 | $-0.05 |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
$0.64
Stock Price
$50.93M
Market Cap
119
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for CytomX Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $138.10M | $101.21M | $53.16M | $69.57M | $100.36M |
| Cost of Revenue | $- | $- | $5.86M | $5.84M | $- |
| Gross Profit | $138.10M | $101.21M | $47.31M | $63.73M | $100.36M |
| Gross Profit Ratio | 100.00% | 100.00% | 88.98% | 91.60% | 100.00% |
| Research and Development Expenses | $83.38M | $77.68M | $111.65M | $114.19M | $112.94M |
| General and Administrative Expenses | $29.73M | $30.02M | $42.85M | $39.16M | $36.03M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $29.73M | $30.02M | $42.85M | $39.16M | $36.03M |
| Other Expenses | $- | $- | $340.00K | $-83.00K | $-27.00K |
| Operating Expenses | $113.11M | $107.70M | $154.50M | $153.35M | $148.97M |
| Cost and Expenses | $113.11M | $107.70M | $154.50M | $153.35M | $148.97M |
| Interest Income | $7.14M | $9.84M | $1.68M | $255.00K | $1.84M |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $2.17M | $5.86M | $5.84M | $5.46M |
| EBITDA | $25.00M | $-4.31M | $-98.89M | $-113.34M | $-77.97M |
| EBITDA Ratio | 18.10% | -4.26% | -190.61% | -120.42% | -45.87% |
| Operating Income | $25.00M | $-6.48M | $-101.33M | $-83.78M | $-48.60M |
| Operating Income Ratio | 18.10% | -6.41% | -190.61% | -120.42% | -48.43% |
| Total Other Income Expenses Net | $7.10M | $9.81M | $2.02M | $172.00K | $1.81M |
| Income Before Tax | $32.09M | $3.32M | $-99.32M | $-83.61M | $-46.80M |
| Income Before Tax Ratio | 23.24% | 3.28% | -186.82% | -120.17% | -46.63% |
| Income Tax Expense | $224.00K | $3.89M | $-2.02M | $-2.96M | $-13.91M |
| Net Income | $31.87M | $-569.00K | $-97.30M | $-80.65M | $-32.88M |
| Net Income Ratio | 23.08% | -0.56% | -183.02% | -115.92% | -32.77% |
| EPS | $0.38 | $-0.01 | $-1.48 | $-1.26 | $-0.71 |
| EPS Diluted | $0.38 | $-0.01 | $-1.48 | $-1.26 | $-0.71 |
| Weighted Average Shares Outstanding | 84.44M | 73.81M | 65.74M | 64.15M | 46.15M |
| Weighted Average Shares Outstanding Diluted | 84.75M | 73.81M | 65.74M | 64.15M | 46.15M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.09M | $33.43M | $25.11M | $41.46M | $26.61M | $26.38M | $24.72M | $23.50M | $946.00K | $16.91M | $18.16M | $17.14M | $19.73M | $17.59M | $16.29M | $15.97M | $16.37M | $17.79M | $16.61M | $49.59M |
| Cost of Revenue | $- | $- | $459.00K | $467.00K | $486.00K | $1.43M | $1.53M | $1.50M | $1.49M | $1.49M | $1.45M | $- | $1.48M | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $38.09M | $33.43M | $24.66M | $41.00M | $26.12M | $24.96M | $23.19M | $22.00M | $-543.00K | $15.43M | $16.71M | $17.14M | $18.24M | $17.59M | $16.29M | $15.97M | $16.37M | $17.79M | $16.61M | $49.59M |
| Gross Profit Ratio | 100.00% | 100.00% | 98.20% | 98.90% | 98.20% | 94.60% | 93.80% | 93.60% | -57.40% | 91.20% | 92.00% | 100.00% | 92.50% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $14.79M | $21.37M | $24.75M | $21.62M | $18.94M | $16.45M | $20.67M | $21.18M | $19.56M | $30.37M | $31.16M | $30.56M | $36.58M | $29.14M | $26.10M | $22.37M | $22.01M | $24.05M | $24.07M | $42.81M |
| General and Administrative Expenses | $5.62M | $7.95M | $8.39M | $7.75M | $7.83M | $6.81M | $7.40M | $7.98M | $10.07M | $10.49M | $11.75M | $10.54M | $9.46M | $11.09M | $9.39M | $9.23M | $9.14M | $8.63M | $8.68M | $9.57M |
| Selling and Marketing Expenses | $- | $- | $-37.00K | $-36.00K | $-37.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.62M | $7.95M | $8.36M | $7.72M | $7.79M | $6.81M | $7.40M | $7.98M | $10.07M | $10.49M | $11.75M | $10.54M | $9.46M | $11.09M | $9.39M | $9.23M | $9.14M | $8.63M | $8.68M | $9.57M |
| Other Expenses | $- | $- | $-2.00K | $-11.00K | $9.00K | $-7.00K | $-47.00K | $15.00K | $1.00K | $30.00K | $296.00K | $13.00K | $7.00K | $-13.00K | $-82.00K | $5.00K | $-28.00K | $-15.00K | $5.00K | $12.00K |
| Operating Expenses | $20.41M | $29.32M | $33.11M | $29.34M | $26.73M | $23.26M | $28.07M | $29.15M | $29.63M | $40.86M | $42.91M | $41.10M | $46.03M | $40.23M | $35.49M | $31.60M | $31.15M | $32.68M | $32.75M | $52.39M |
| Cost and Expenses | $20.41M | $29.32M | $33.57M | $29.81M | $27.21M | $23.26M | $28.07M | $29.15M | $29.63M | $40.86M | $42.91M | $41.10M | $46.03M | $40.23M | $35.49M | $31.60M | $31.15M | $32.68M | $32.75M | $52.39M |
| Interest Income | $1.28M | $1.69M | $1.97M | $2.19M | $2.50M | $2.70M | $2.31M | $2.33M | $732.00K | $616.00K | $262.00K | $68.00K | $73.00K | $70.00K | $44.00K | $68.00K | $106.00K | $200.00K | $454.00K | $1.07M |
| Interest Expense | $- | $- | $- | $- | $2.34M | $- | $- | $- | $- | $616.00K | $262.00K | $68.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $413.00K | $429.00K | $459.00K | $467.00K | $486.00K | $1.43M | $1.53M | $1.50M | $1.49M | $1.49M | $1.45M | $1.43M | $1.48M | $1.47M | $1.45M | $1.43M | $662.00K | $652.00K | $622.00K | $637.00K |
| EBITDA | $18.09M | $4.54M | $-8.45M | $12.12M | $-120.00K | $3.12M | $-2.74M | $-5.06M | $-32.96M | $-29.09M | $-29.44M | $-31.46M | $-24.75M | $-21.96M | $-18.53M | $-14.95M | $-14.12M | $-14.24M | $-15.52M | $-2.16M |
| EBITDA Ratio | 47.49% | 13.58% | -31.83% | 29.24% | -0.45% | 11.84% | -11.07% | -21.52% | -2967.97% | -137.86% | -132.85% | -136.34% | -129.94% | -124.87% | -113.75% | -93.63% | -86.22% | -80.07% | -93.42% | -4.35% |
| Operating Income | $17.68M | $4.11M | $-8.45M | $11.66M | $-606.00K | $3.12M | $-3.35M | $-5.65M | $-28.68M | $-23.94M | $-24.74M | $-23.97M | $-26.31M | $-22.64M | $-19.20M | $-15.63M | $-14.78M | $-14.89M | $-16.14M | $-2.79M |
| Operating Income Ratio | 46.41% | 12.30% | -33.65% | 28.11% | -2.28% | 11.84% | -13.54% | -24.06% | -3032.24% | -141.54% | -136.21% | -139.86% | -133.36% | -128.74% | -117.91% | -97.85% | -90.26% | -83.74% | -97.17% | -5.63% |
| Total Other Income Expenses Net | $1.26M | $1.69M | $1.97M | $2.18M | $2.51M | $2.69M | $2.26M | $2.34M | $733.00K | $6.41M | $558.00K | $81.00K | $80.00K | $57.00K | $-38.00K | $73.00K | $78.00K | $185.00K | $459.00K | $1.09M |
| Income Before Tax | $18.94M | $5.80M | $-6.48M | $13.84M | $1.91M | $5.82M | $-1.09M | $-3.31M | $-27.95M | $-23.30M | $-24.18M | $-23.89M | $-26.23M | $-22.58M | $-19.24M | $-15.55M | $-14.70M | $-14.71M | $-15.68M | $-1.71M |
| Income Before Tax Ratio | 49.72% | 17.34% | -25.81% | 33.38% | 7.16% | 22.04% | -4.40% | -14.09% | -2954.76% | -137.72% | -133.14% | -139.38% | -132.95% | -128.41% | -118.14% | -97.39% | -89.79% | -82.70% | -94.41% | -3.44% |
| Income Tax Expense | $62.00K | $61.00K | $51.00K | $49.00K | $1.07M | $2.82M | $-2.31M | $-2.34M | $-1.37M | $-646.00K | $-558.00K | $-81.00K | $-73.00K | $-70.00K | $-44.00K | $-68.00K | $-106.00K | $-200.00K | $-454.00K | $-13.91M |
| Net Income | $18.88M | $5.74M | $-6.53M | $13.79M | $837.00K | $2.99M | $-1.09M | $-969.00K | $-26.58M | $-22.65M | $-23.63M | $-23.80M | $-26.23M | $-22.58M | $-19.24M | $-15.55M | $-14.70M | $-14.71M | $-15.68M | $12.21M |
| Net Income Ratio | 49.55% | 17.16% | -26.02% | 33.26% | 3.15% | 11.34% | -4.40% | -4.12% | -2809.73% | -133.90% | -130.06% | -138.91% | -132.95% | -128.41% | -118.14% | -97.39% | -89.79% | -82.70% | -94.41% | 24.61% |
| EPS | $0.22 | $0.07 | $-0.08 | $0.17 | $0.01 | $0.04 | $-0.02 | $-0.01 | $-0.40 | $-0.34 | $-0.36 | $-0.36 | $-0.40 | $-0.35 | $-0.30 | $-0.26 | $-0.32 | $-0.32 | $-0.34 | $0.27 |
| EPS Diluted | $0.22 | $0.07 | $-0.08 | $0.17 | $0.01 | $0.04 | $-0.02 | $-0.01 | $-0.40 | $-0.34 | $-0.36 | $-0.36 | $-0.40 | $-0.35 | $-0.30 | $-0.26 | $-0.32 | $-0.32 | $-0.34 | $0.26 |
| Weighted Average Shares Outstanding | 84.44M | 85.09M | 84.88M | 82.03M | 67.31M | 80.73M | 66.54M | 66.25M | 66.23M | 65.91M | 65.54M | 65.39M | 65.21M | 64.53M | 65.06M | 60.97M | 46.20M | 46.20M | 46.06M | 45.72M |
| Weighted Average Shares Outstanding Diluted | 84.75M | 85.20M | 84.88M | 82.63M | 67.31M | 80.99M | 66.54M | 66.25M | 66.23M | 65.91M | 65.54M | 65.39M | 65.21M | 65.21M | 65.06M | 60.97M | 46.20M | 46.20M | 46.06M | 47.04M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $38.05M | $17.17M | $193.65M | $205.53M | $191.86M |
| Short Term Investments | $62.57M | $157.34M | $- | $99.70M | $124.26M |
| Cash and Short Term Investments | $100.62M | $174.51M | $193.65M | $305.23M | $316.12M |
| Net Receivables | $3.10M | $3.43M | $35.99M | $790.00K | $798.00K |
| Inventory | $- | $- | $- | $1 | $1 |
| Other Current Assets | $3.58M | $5.00M | $7.47M | $8.57M | $14.19M |
| Total Current Assets | $107.31M | $182.94M | $237.10M | $310.30M | $324.01M |
| Property Plant Equipment Net | $10.60M | $16.18M | $21.02M | $25.32M | $29.45M |
| Goodwill | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K |
| Intangible Assets | $583.00K | $729.00K | $875.00K | $1.02M | $1.17M |
| Goodwill and Intangible Assets | $1.53M | $1.68M | $1.82M | $1.97M | $2.12M |
| Long Term Investments | $- | $- | $917.00K | $917.00K | $917.00K |
| Tax Assets | $- | $- | $3.60M | $4.61M | $5.54M |
| Other Non-Current Assets | $1.09M | $1.00M | $-3.57M | $-3.71M | $-3.37M |
| Total Non-Current Assets | $13.23M | $18.86M | $23.79M | $29.11M | $34.65M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $120.53M | $201.79M | $260.89M | $339.41M | $358.66M |
| Account Payables | $1.09M | $1.46M | $2.81M | $2.82M | $3.00M |
| Short Term Debt | $5.14M | $4.59M | $4.08M | $3.62M | $3.19M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $67.20M | $132.27M | $121.27M | $69.26M | $74.87M |
| Other Current Liabilities | $12.34M | $17.60M | $24.45M | $30.62M | $19.86M |
| Total Current Liabilities | $85.77M | $155.91M | $152.61M | $106.32M | $100.92M |
| Long Term Debt | $4.24M | $9.38M | $27.95M | $36.11M | $43.35M |
| Deferred Revenue Non-Current | $- | $80.05M | $180.06M | $125.66M | $186.26M |
| Deferred Tax Liabilities Non-Current | $- | $- | $3.60M | $4.61M | $5.54M |
| Other Non-Current Liabilities | $30.98M | $3.89M | $-13.97M | $100.23M | $-21.68M |
| Total Non-Current Liabilities | $35.22M | $93.33M | $194.03M | $143.72M | $207.94M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $120.99M | $249.24M | $346.64M | $250.03M | $308.86M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K |
| Retained Earnings | $-691.58M | $-723.45M | $-722.88M | $-533.72M | $-450.12M |
| Accumulated Other Comprehensive Income Loss | $27.00K | $95.00K | $10.00K | $-242.00K | $-47.00K |
| Other Total Stockholders Equity | $691.10M | $675.90M | $637.12M | $623.34M | $499.96M |
| Total Stockholders Equity | $-456.00K | $-47.45M | $-85.75M | $89.38M | $49.80M |
| Total Equity | $-456.00K | $-47.45M | $-85.75M | $89.38M | $49.80M |
| Total Liabilities and Stockholders Equity | $120.53M | $201.79M | $260.89M | $339.41M | $358.66M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $120.53M | $201.79M | $260.89M | $339.41M | $358.66M |
| Total Investments | $62.57M | $157.34M | $917.00K | $99.70M | $124.26M |
| Total Debt | $9.38M | $13.97M | $18.06M | $18.06M | $24.87M |
| Net Debt | $-28.67M | $-3.20M | $-175.59M | $-187.47M | $-166.99M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $38.05M | $40.58M | $43.25M | $36.19M | $17.17M | $26.02M | $57.54M | $56.36M | $193.65M | $95.04M | $129.29M | $163.49M | $205.53M | $236.28M | $256.15M | $329.67M | $191.86M | $176.81M | $291.39M | $143.29M |
| Short Term Investments | $62.57M | $77.01M | $93.94M | $114.10M | $157.34M | $168.09M | $123.32M | $148.15M | $- | $99.25M | $98.88M | $99.04M | $99.70M | $5.00K | $10.03M | $64.13M | $124.26M | $144.27M | $55.01M | $104.64M |
| Cash and Short Term Investments | $100.62M | $117.59M | $137.18M | $150.28M | $174.51M | $194.11M | $180.86M | $204.50M | $193.65M | $194.29M | $228.16M | $262.53M | $305.23M | $236.29M | $266.18M | $393.80M | $316.12M | $321.08M | $346.40M | $247.92M |
| Net Receivables | $3.10M | $3.35M | $2.77M | $13.18M | $3.43M | $2.42M | $1.90M | $1.09M | $35.99M | $1.71M | $1.01M | $1.02M | $790.00K | $887.00K | $931.00K | $756.00K | $798.00K | $13.60M | $13.27M | $143.07M |
| Inventory | $- | $- | $- | $- | $- | $1 | $1 | $1 | $- | $1 | $- | $1 | $1 | $1 | $1 | $1 | $1 | $- | $- | $2 |
| Other Current Assets | $3.58M | $3.24M | $3.12M | $3.79M | $5.00M | $4.67M | $5.04M | $6.68M | $7.47M | $8.56M | $7.18M | $9.80M | $8.57M | $7.64M | $3.90M | $10.91M | $14.19M | $5.62M | $6.90M | $9.07M |
| Total Current Assets | $107.31M | $124.18M | $143.08M | $167.25M | $182.94M | $201.20M | $187.80M | $212.28M | $237.10M | $200.28M | $232.77M | $268.44M | $310.30M | $241.00M | $271.00M | $400.01M | $324.01M | $340.31M | $366.57M | $400.07M |
| Property Plant Equipment Net | $10.60M | $12.13M | $13.54M | $14.80M | $16.18M | $17.24M | $18.62M | $19.62M | $21.02M | $22.54M | $23.61M | $24.63M | $25.32M | $26.44M | $27.66M | $28.91M | $29.45M | $30.43M | $31.43M | $32.08M |
| Goodwill | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K | $949.00K |
| Intangible Assets | $583.00K | $620.00K | $656.00K | $693.00K | $729.00K | $766.00K | $802.00K | $839.00K | $875.00K | $911.00K | $948.00K | $984.00K | $1.02M | $1.06M | $1.09M | $1.13M | $1.17M | $1.20M | $1.24M | $1.28M |
| Goodwill and Intangible Assets | $1.53M | $1.57M | $1.60M | $1.64M | $1.68M | $1.72M | $1.75M | $1.79M | $1.82M | $1.86M | $1.90M | $1.93M | $1.97M | $2.01M | $2.04M | $2.08M | $2.12M | $2.15M | $2.19M | $2.23M |
| Long Term Investments | $- | $- | $917.00K | $917.00K | $917.00K | $917.00K | $917.00K | $917.00K | $917.00K | $917.00K | $917.00K | $917.00K | $917.00K | $99.97M | $99.91M | $917.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $-1 | $-1 | $3.36M | $-917.00K | $-917.00K | $-917.00K | $3.60M | $-917.00K | $-917.00K | $-917.00K | $4.61M | $- | $- | $-917.00K | $- | $- | $- | $- |
| Other Non-Current Assets | $1.09M | $1.10M | $76.00K | $80.00K | $83.00K | $1.00M | $1.01M | $944.00K | $-3.57M | $1.81M | $1.81M | $902.00K | $-3.71M | $1.82M | $1.82M | $2.25M | $3.09M | $2.30M | $2.30M | $2.30M |
| Total Non-Current Assets | $13.23M | $14.80M | $16.14M | $17.44M | $22.21M | $19.96M | $21.38M | $22.35M | $23.79M | $26.21M | $27.32M | $28.38M | $29.11M | $130.24M | $131.44M | $34.15M | $34.65M | $34.88M | $35.91M | $36.60M |
| Other Assets | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $120.53M | $138.98M | $159.22M | $184.69M | $205.15M | $221.17M | $209.19M | $234.63M | $260.89M | $226.49M | $260.09M | $296.82M | $339.41M | $371.23M | $402.44M | $434.16M | $358.66M | $375.18M | $402.48M | $436.66M |
| Account Payables | $1.09M | $1.42M | $611.00K | $1.96M | $1.46M | $1.71M | $1.03M | $2.20M | $2.81M | $5.18M | $1.92M | $1.72M | $2.82M | $1.52M | $1.75M | $2.58M | $3.00M | $3.64M | $4.93M | $3.78M |
| Short Term Debt | $5.14M | $5.00M | $9.72M | $4.72M | $9.18M | $4.46M | $4.33M | $4.20M | $4.08M | $3.96M | $3.85M | $3.73M | $3.62M | $3.51M | $3.40M | $3.30M | $3.19M | $3.10M | $3.00M | $2.90M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $67.20M | $96.06M | $123.77M | $123.63M | $132.27M | $124.40M | $120.28M | $126.78M | $121.27M | $61.33M | $65.79M | $70.01M | $69.26M | $73.09M | $72.37M | $76.64M | $74.87M | $74.44M | $72.71M | $73.87M |
| Other Current Liabilities | $12.34M | $16.74M | $11.78M | $14.22M | $17.86M | $16.23M | $15.74M | $18.07M | $24.45M | $27.38M | $27.89M | $27.30M | $30.62M | $21.66M | $15.85M | $15.53M | $19.86M | $20.85M | $18.15M | $25.45M |
| Total Current Liabilities | $85.77M | $119.23M | $142.86M | $144.54M | $155.91M | $146.79M | $141.38M | $151.26M | $152.61M | $97.84M | $99.44M | $102.77M | $106.32M | $99.77M | $93.38M | $98.05M | $100.92M | $102.03M | $98.78M | $106.00M |
| Long Term Debt | $4.24M | $5.60M | $6.88M | $8.15M | $18.77M | $21.19M | $23.49M | $12.87M | $27.95M | $30.11M | $32.15M | $34.15M | $36.11M | $38.03M | $39.84M | $41.61M | $43.35M | $45.05M | $46.65M | $48.21M |
| Deferred Revenue Non-Current | $26.86M | $- | $36.71M | $59.74M | $80.05M | $112.26M | $140.87M | $157.13M | $180.06M | $85.12M | $95.86M | $108.79M | $125.66M | $140.77M | $158.19M | $169.28M | $186.26M | $202.56M | $221.54M | $236.79M |
| Deferred Tax Liabilities Non-Current | $- | $- | $-1 | $-1 | $3.36M | $- | $- | $-157.13M | $3.60M | $-85.12M | $-95.86M | $-108.79M | $4.61M | $-140.77M | $-158.19M | $-20.81M | $-21.68M | $-22.52M | $-23.32M | $-24.11M |
| Other Non-Current Liabilities | $4.12M | $37.61M | $3.99M | $3.94M | $-5.49M | $-7.84M | $-11.53M | $- | $-13.97M | $-15.05M | $-16.08M | $-17.08M | $-18.06M | $-19.02M | $-19.92M | $-20.81M | $-21.68M | $-22.52M | $-23.32M | $-24.11M |
| Total Non-Current Liabilities | $35.22M | $43.20M | $47.59M | $71.83M | $96.69M | $125.61M | $152.84M | $170.00M | $194.03M | $100.18M | $111.94M | $125.86M | $143.72M | $159.79M | $178.11M | $190.09M | $207.94M | $225.09M | $244.87M | $260.89M |
| Other Liabilities | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $120.99M | $162.43M | $190.45M | $216.37M | $252.60M | $272.40M | $294.21M | $321.27M | $346.64M | $198.02M | $211.38M | $228.63M | $250.03M | $259.56M | $271.49M | $288.14M | $308.86M | $327.12M | $343.65M | $366.89M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K |
| Retained Earnings | $-691.58M | $-710.46M | $-716.19M | $-709.66M | $-723.45M | $-724.28M | $-727.28M | $-726.19M | $-722.88M | $-605.09M | $-581.79M | $-557.61M | $-533.72M | $-507.50M | $-484.91M | $-465.67M | $-450.12M | $-435.41M | $-420.70M | $-405.02M |
| Accumulated Other Comprehensive Income Loss | $27.00K | $40.00K | $-4.00K | $-10.00K | $95.00K | $-63.00K | $35.00K | $26.00K | $10.00K | $-795.00K | $-1.16M | $-919.00K | $-242.00K | $52.00K | $15.00K | $-43.00K | $-47.00K | $-47.00K | $16.00K | $336.00K |
| Other Total Stockholders Equity | $691.10M | $686.96M | $684.97M | $677.99M | $675.90M | $673.11M | $642.21M | $639.53M | $637.12M | $634.36M | $631.66M | $626.72M | $623.34M | $619.12M | $615.85M | $611.73M | $499.96M | $483.52M | $479.52M | $474.45M |
| Total Stockholders Equity | $-456.00K | $-23.45M | $-31.23M | $-31.68M | $-47.45M | $-51.24M | $-85.03M | $-86.64M | $-85.75M | $28.47M | $48.71M | $68.19M | $89.38M | $111.67M | $130.95M | $146.02M | $49.80M | $48.06M | $58.83M | $69.77M |
| Total Equity | $-456.00K | $-23.45M | $-31.23M | $-31.68M | $-47.45M | $-51.24M | $-85.03M | $-86.64M | $-85.75M | $28.47M | $48.71M | $68.19M | $89.38M | $111.67M | $130.95M | $146.02M | $49.80M | $48.06M | $58.83M | $69.77M |
| Total Liabilities and Stockholders Equity | $120.53M | $138.98M | $159.22M | $184.69M | $205.15M | $221.17M | $209.19M | $234.63M | $260.89M | $226.49M | $260.09M | $296.82M | $339.41M | $371.23M | $402.44M | $434.16M | $358.66M | $375.18M | $402.48M | $436.66M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $120.53M | $138.98M | $159.22M | $184.69M | $205.15M | $221.17M | $209.19M | $234.63M | $260.89M | $226.49M | $260.09M | $296.82M | $339.41M | $371.23M | $402.44M | $434.16M | $358.66M | $375.18M | $402.48M | $436.66M |
| Total Investments | $62.57M | $77.01M | $94.85M | $115.02M | $158.25M | $168.09M | $123.32M | $148.15M | $917.00K | $99.25M | $98.88M | $99.04M | $99.70M | $99.97M | $109.94M | $64.13M | $124.26M | $144.27M | $55.01M | $104.64M |
| Total Debt | $9.38M | $10.60M | $11.75M | $12.87M | $13.97M | $15.05M | $16.08M | $17.08M | $18.06M | $19.02M | $19.92M | $20.81M | $21.67M | $22.53M | $23.32M | $24.10M | $24.87M | $25.62M | $26.32M | $27.01M |
| Net Debt | $-28.67M | $-29.98M | $-31.50M | $-23.31M | $-3.20M | $-10.97M | $-41.46M | $-39.28M | $-175.59M | $-76.02M | $-109.37M | $-142.68M | $-183.86M | $-213.76M | $-232.82M | $-305.56M | $-166.99M | $-151.19M | $-265.07M | $-116.28M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $31.87M | $-569.00K | $-99.32M | $-83.61M | $-32.88M |
| Depreciation and Amortization | $146.00K | $2.17M | $2.44M | $2.71M | $2.57M |
| Deferred Income Tax | $- | $- | $- | $272.00K | $-236.00K |
| Stock Based Compensation | $7.67M | $8.56M | $13.12M | $13.17M | $14.79M |
| Change in Working Capital | $-126.42M | $-62.51M | $-30.65M | $-54.70M | $18.13M |
| Accounts Receivables | $329.00K | $32.55M | $-35.20M | $8.00K | $-785.00K |
| Inventory | $- | $- | $- | $11.64M | $-11.12M |
| Accounts Payables | $-297.00K | $-1.43M | $68.00K | $-139.00K | $-857.00K |
| Other Working Capital | $-126.45M | $-93.64M | $4.47M | $-66.21M | $30.89M |
| Other Non Cash Items | $501.00K | $-3.69M | $3.62M | $3.13M | $2.89M |
| Net Cash Provided by Operating Activities | $-86.23M | $-56.03M | $-110.79M | $-119.03M | $5.26M |
| Investments in Property Plant and Equipment | $-310.00K | $-840.00K | $-1.74M | $-1.61M | $-2.31M |
| Acquisitions Net | $- | $- | $- | $-24.10M | $16.41M |
| Purchases of Investments | $-155.49M | $-424.83M | $- | $-99.90M | $-199.11M |
| Sales Maturities of Investments | $255.50M | $275.00M | $100.00M | $124.00M | $182.70M |
| Other Investing Activities | $- | $- | $100.00M | $24.10M | $-16.41M |
| Net Cash Used for Investing Activities | $99.70M | $-150.67M | $98.26M | $22.49M | $-18.72M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $6.91M | $30.23M | $648.00K | $107.71M | $11.29M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $613.00K | $30.23M | $648.00K | $2.50M | $5.61M |
| Net Cash Used Provided by Financing Activities | $7.52M | $30.23M | $648.00K | $110.21M | $16.89M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $20.99M | $-176.48M | $-11.88M | $13.67M | $3.43M |
| Cash at End of Period | $39.08M | $18.09M | $194.57M | $206.45M | $192.78M |
| Cash at Beginning of Period | $18.09M | $194.57M | $206.45M | $192.78M | $189.34M |
| Operating Cash Flow | $-86.23M | $-56.03M | $-110.79M | $-119.03M | $5.26M |
| Capital Expenditure | $-310.00K | $-840.00K | $-1.74M | $-1.61M | $-2.31M |
| Free Cash Flow | $-86.54M | $-56.88M | $-112.53M | $-120.64M | $2.95M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $18.88M | $5.74M | $-6.53M | $13.79M | $837.00K | $2.99M | $-1.09M | $-3.31M | $-27.95M | $-23.30M | $-24.18M | $-23.89M | $-26.23M | $-22.58M | $-19.24M | $-15.55M | $-14.70M | $-14.71M | $-15.68M | $12.21M |
| Depreciation and Amortization | $413.00K | $-817.00K | $459.00K | $467.00K | $486.00K | $484.00K | $610.00K | $595.00K | $608.00K | $623.00K | $610.00K | $602.00K | $675.00K | $680.00K | $677.00K | $674.00K | $662.00K | $652.00K | $622.00K | $637.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-4.87M | $-1.93M | $-1.73M | $- | $- | $- | $- | $- | $-15.00K | $6.00K | $140.00K | $141.00K | $- | $- | $- | $- |
| Stock Based Compensation | $1.88M | $2.00M | $1.88M | $1.91M | $2.55M | $1.23M | $2.37M | $2.41M | $2.57M | $2.69M | $4.49M | $3.37M | $3.54M | $3.16M | $3.42M | $3.03M | $3.42M | $3.84M | $3.51M | $4.01M |
| Change in Working Capital | $-41.46M | $56.26M | $-14.93M | $-41.33M | $-24.58M | $-21.95M | $-26.27M | $10.29M | $22.25M | $-14.71M | $-15.98M | $-22.21M | $-9.98M | $-11.76M | $-13.97M | $-18.99M | $-9.80M | $-14.43M | $108.83M | $-66.47M |
| Accounts Receivables | $249.00K | $-577.00K | $10.40M | $-9.74M | $-1.01M | $-516.00K | $-813.00K | $34.90M | $-34.21M | $-696.00K | $-58.00K | $-232.00K | $97.00K | $44.00K | $-175.00K | $42.00K | $-255.00K | $-337.00K | $129.80M | $-130.00M |
| Inventory | $- | $- | $- | $- | $-1 | $2.38M | $-1.54M | $- | $- | $- | $- | $- | $7.65M | $5.08M | $2.44M | $-3.53M | $6.92M | $4.00M | $-5.10M | $-16.94M |
| Accounts Payables | $-261.00K | $811.00K | $-1.43M | $581.00K | $-328.00K | $676.00K | $-1.16M | $-618.00K | $-2.37M | $3.29M | $216.00K | $-1.06M | $1.22M | $-185.00K | $-881.00K | $-292.00K | $-587.00K | $-849.00K | $527.00K | $52.00K |
| Other Working Capital | $-41.45M | $56.02M | $-23.90M | $-32.17M | $-23.23M | $-24.50M | $-22.76M | $-23.99M | $58.83M | $-17.30M | $-16.14M | $-20.92M | $-18.94M | $-16.70M | $-15.36M | $-15.21M | $-15.88M | $-17.25M | $-16.40M | $80.42M |
| Other Non Cash Items | $376.00K | $-83.90M | $-6.60M | $11.12M | $3.60M | $942.00K | $922.00K | $-634.00K | $1.13M | $848.00K | $828.00K | $809.00K | $808.00K | $791.00K | $775.00K | $759.00K | $2.99M | $-27.00K | $-187.00K | $-127.00K |
| Net Cash Provided by Operating Activities | $-19.91M | $-20.73M | $-19.55M | $-26.05M | $-21.96M | $-18.24M | $-25.18M | $9.35M | $-1.39M | $-33.84M | $-34.24M | $-41.31M | $-31.19M | $-29.70M | $-28.20M | $-29.94M | $-17.43M | $-24.68M | $97.10M | $-49.74M |
| Investments in Property Plant and Equipment | $-80.00K | $-19.00K | $-96.00K | $-115.00K | $-266.00K | $-9.00K | $-517.00K | $-48.00K | $-182.00K | $-410.00K | $-412.00K | $-736.00K | $-245.00K | $-268.00K | $-114.00K | $-982.00K | $-445.00K | $-778.00K | $-37.00K | $-1.05M |
| Acquisitions Net | $- | $- | $- | $- | $-13.13M | $42.93M | $-100.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-49.78M | $-12.31M | $-93.39M | $- | $-111.87M | $-92.93M | $-73.44M | $-146.59M | $- | $- | $- | $- | $- | $- | $-99.90M | $- | $-10.10M | $-144.30M | $- | $-44.71M |
| Sales Maturities of Investments | $65.00M | $30.50M | $115.00M | $45.00M | $125.00M | $50.00M | $100.00M | $- | $100.00M | $- | $- | $- | $- | $10.00M | $54.00M | $59.99M | $30.00M | $55.01M | $49.49M | $48.20M |
| Other Investing Activities | $- | $- | $- | $45.00M | $13.13M | $-42.93M | $100.00M | $-146.59M | $100.00M | $- | $- | $- | $- | $10.00M | $-45.90M | $59.99M | $19.90M | $-89.29M | $49.49M | $3.49M |
| Net Cash Used for Investing Activities | $15.13M | $18.17M | $21.51M | $44.88M | $12.87M | $-42.94M | $26.04M | $-146.64M | $99.82M | $-410.00K | $-412.00K | $-736.00K | $-245.00K | $9.73M | $-46.01M | $59.01M | $19.45M | $-90.07M | $49.45M | $2.44M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $2.07M | $-430.00K | $5.10M | $174.00K | $244.00K | $29.67M | $317.00K | $- | $648.00K | $- | $451.00K | $7.00K | $683.00K | $104.00K | $108.30M | $107.71M | $11.29M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $183.00K | $-4.84M | $5.10M | $174.00K | $244.00K | $29.67M | $317.00K | $- | $190.00K | $- | $451.00K | $7.00K | $683.00K | $104.00K | $691.00K | $1.02M | $13.02M | $167.00K | $1.55M | $2.16M |
| Net Cash Used Provided by Financing Activities | $2.25M | $- | $5.10M | $174.00K | $244.00K | $29.67M | $317.00K | $- | $190.00K | $- | $451.00K | $7.00K | $683.00K | $104.00K | $691.00K | $108.73M | $13.02M | $167.00K | $1.55M | $2.16M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-2.52M | $-2.56M | $7.06M | $19.01M | $-8.85M | $-31.51M | $1.18M | $-137.29M | $98.61M | $-34.25M | $-34.20M | $-42.04M | $-30.75M | $-19.86M | $-73.52M | $137.81M | $15.05M | $-114.58M | $148.10M | $-45.14M |
| Cash at End of Period | $39.08M | $41.60M | $43.25M | $36.19M | $17.17M | $26.94M | $58.45M | $57.27M | $194.57M | $95.95M | $130.21M | $164.41M | $206.45M | $237.20M | $257.06M | $330.58M | $192.78M | $177.73M | $292.31M | $144.20M |
| Cash at Beginning of Period | $41.60M | $44.16M | $36.19M | $17.17M | $26.02M | $58.45M | $57.27M | $194.57M | $95.95M | $130.21M | $164.41M | $206.45M | $237.20M | $257.06M | $330.58M | $192.78M | $177.73M | $292.31M | $144.20M | $189.34M |
| Operating Cash Flow | $-19.91M | $-20.73M | $-19.55M | $-26.05M | $-21.96M | $-18.24M | $-25.18M | $9.35M | $-1.39M | $-33.84M | $-34.24M | $-41.31M | $-31.19M | $-29.70M | $-28.20M | $-29.94M | $-17.43M | $-24.68M | $97.10M | $-49.74M |
| Capital Expenditure | $-80.00K | $-19.00K | $-96.00K | $-115.00K | $-266.00K | $-9.00K | $-517.00K | $-48.00K | $-182.00K | $-410.00K | $-412.00K | $-736.00K | $-245.00K | $-268.00K | $-114.00K | $-982.00K | $-445.00K | $-778.00K | $-37.00K | $-1.05M |
| Free Cash Flow | $-19.99M | $-20.75M | $-19.64M | $-26.16M | $-22.23M | $-18.25M | $-25.70M | $9.30M | $-1.58M | $-34.25M | $-34.65M | $-42.05M | $-31.44M | $-29.97M | $-28.31M | $-30.92M | $-17.87M | $-25.46M | $97.06M | $-50.79M |
CytomX Therapeutics Dividends
Explore CytomX Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
CytomX Therapeutics News
Read the latest news about CytomX Therapeutics, including recent articles, headlines, and updates.
CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ET Company Participants Chris Ogden - CFO Sean McCarthy - Chairman and CEO Conference Call Participants Roger Song - Jefferies Joe Catanzaro - Piper Sandler Anupam Rama - JPMorgan Peter Lawson - Barclays Operator Good afternoon, everyone. Thank you for standing by.
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets.
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 -
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Chris Ogden - CFO Sean A. McCarthy - Chairman and CEO Conference Call Participants Joseph Catanzaro - Piper Sandler Liang Cheng - Jefferies Etzer Darout - BMO Capital Markets Anupam Rama - J.P.
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors.
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.
No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock took a round trip from $1.80 to $5.80 and back.
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -
Why Is CytomX (CTMX) Stock Up 180% Today?
CytomX (NASDAQ: CTMX ) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report. The oncology-focused biopharmaceutical company told traders that it will release its earnings report for the first quarter of 2024 when markets close on May 8, 2024.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CTMX.